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Abstract 
Review on ING1, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: p24ING1c, p33, p33ING1, 
p33ING1b, p47, p47ING1a 
HGNC (Hugo): ING1 
Location: 13q34 
DNA/RNA 
Description 
In 1996 Karl Riabowol's group identified a new 
Tumor Suppressor Gene (TSG) by using subtractive 
hybridization between cDNAs from normal 
mammary epithelial cells and mammary epithelial 
cells from tumor (breast cancer cell-lines). This 
experiment was followed by an in vivo screen for 
tumourigenesis. Using this method, the authors 
identified a new candidate TSG they named ING1 
for INhibitor of Growth 1 (Garkavtsev et al., 1996). 
Transcription 
The ING1 gene has been mapped to chromosome 13 
at locus 13q34 close to the telomeric region (Figure 
1). Human ING1 is made of four exons, exon 1a, 1b, 
1c, and 2, resulting in five transcribed variants 
(ING1a, ING1b, ING1c, and ING1d) (Figure 2). 
Pseudogene 
INGX is the pseudogene of ING1 (He et al., 2005). 
Figure1. Chromosomal localization of the ING1 gene in Homo sapiens. 
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Figure 2. Structure and transcripts of Human ING1 genes. Coding regions are in dark blue and non-coding regions are 
represented in light blue. For ING1c v2 and v5: Exons E1d and E1balt (alternative) are represented in yellow. They both code for 
the same protein: ING1c (Figure 3). 
 
Protein 
Description 
The amino acid sequence alignment of human ING 
proteins revealed several conserved regions in their 
C-terminal part: a Novel Conserved Region (NCR), 
a Nuclear Localization Signal (NLS), a Plant Homeo 
Domain (PHD) and a PolyBasic Region (PBR). 
The ING proteins are characterized by the presence 
of a highly conserved PHD in their C-terminal part. 
This domain is commonly found in proteins involved 
in chromatin modification (Bienz, 2006; Mellor, 
2006). In the N-terminal part of ING1b isoform, 
which is the most abundant isoform with ING1a, 
there is also a PCNA Interacting Protein motif (PIP) 
and Partial Bromo Domain (PBD) (Figure 3). 
Expression 
ING1 is ubiquitously expressed in mammalian 
tissues (Walzak et al., 2008). 
Localisation 
The ING1 protein contains an NLS domain, so it is 
mainly located in the nucleus. Members of the 14-3-
3 family are able to interact with ING1 
phosphorylated on serine 199 leading to its 
relocalisation to the cytoplasm (Gong et al., 2006). 
Recently, it has been found that ING1b translocates 
also into mitochondria after UV or IR. This 
translocation is independent of p53 (Bose et al., 
2013). 
Function 
ING1 has been identified as a tumor suppressor gene 
with Gatekeepers and Caretakers functions. 
Initially ING1 has been characterized as gatekeeper 
genes which are known to regulate the growth of 
tumors through senescence, apoptosis and cell cycle 
regulation. Indeed, ING1 is involved in the 
regulation of the cell cycle arrest, apoptosis and 
senescence. 
Firtsly, ING1b has been described to physically 
interact with the tumor suppressor protein p53 and 
being necessary for its transcriptional activity 
(Garkavtsev et al., 1998). ING1 is also involved in 
the regulation of p53 activity. Under stress, ING1b 
interact with PI5P in order to activate the p300 
acetylase which acetylates p53 on lysine 382. This 
acetylation promotes the transcription of factors 
involved in cell cycle arrest, senescence and 
apoptosis (p21, Bax) (Garkavtsev et al., 1998; 
Kataoka et al., 2003).  
ING1b is also able to interact with SIRT1, a histone 
deacetylase known for the p53 deacetylation. SIRT1 
interaction with ING1b competitively inhibits its 
interaction with p53 leading to the maintenance of 
p53 activity (Kataoka et al., 2003). Moreover, 
ING1b is known to stabilize p53 by disrupting the 
regulation of p53 by MDM2 (Leung et al., 2002). 
ING1 functions can also be independent of p53 
signaling pathways. ING1 has been described to 
interact with the Sin3/HDAC1/HDAC2/SAP30 
complex through a direct interaction with SAP30 
(Kuzmichev et al., 2002). ING1b has also been 
reported to increase the expression of Heat Shock 
Protein 70 (HSP70). This induction of HSP70 
required the amino terminus of ING1b but not the 
PHD, PBR and NLS region (Feng et al., 2006). 
HSP70 is known to inhibit the NF-kB pathways (Ran 
et al., 2004; Shi et al., 2006). More recently, it has 
been shown that the C-terminal PHD of ING1 
interacts with histone H3 trimethylated at Lys4 
(H3K4me3). This interaction is involved in DNA 
repair and apoptotic activities of ING1 (Peña et al., 
2008).  
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Figure 3. Schematic representation of ING1 proteins structure. In the C-terminal part: Novel Conserved Region (NCR), 
Nuclear Localization Signal (NLS), Plant Homeo Domain (PHD) and PolyBasic Region (PBR). In the N-terminal part of 
p33ING1b: PCNA Interacting Protein motif (PIP) and Partial Bromo Domain (PBD). 
 
 
Under stress, ING1 interaction with H3K4me4 leads 
to the recruitment of the Sin3/HDAC1-2/SAP30 
transcriptional repressor complex. Under UV stress, 
ING1b targets the nucleolus and stabilizes Cellular 
Senescence-Inhibited Gene (CSIG) through its 
Nucleolar Targeting Signal (NTS). This interaction 
is required for ING1b dependent apoptosis after UV 
stress (Li et al., 2012). 
More recently, ING1 has been characterized as a 
caretaker gene which controls the integrity of the 
genome.Indeed, ING1b is involved in DNA repair in 
response to UV. ING1b overexpression has been 
described to enhance repair of UV-damaged DNA in 
a p53 dependent manner. Furthermore, binding 
between ING1b and Growth Arrest and DNA 
Damage 45 (GADD45) has been reported.  
These findings suggest that ING1b cooperates with 
GADD45 and p53 in Nucleotide Excision Repair 
(NER) (Cheung Jr. et al., 2001).  
Interestingly, ING1b is also required for PCNA 
monoubiquitination in response to UV.  
More precisely, ING1b is necessary for the loading 
of the E3 ubiquitin ligase Rad18 at stalled replication 
forks through histone H4 acetylation (Wong et al., 
2011). 
Homology 
The C-terminal part of ING proteins is highly-
conserved through human to plant, especially the 
PHD-finger motif.  
There are five human ING genes (ING1, ING2, 
ING3, ING4, and ING5) which encode multiple 
isoforms via splicing. 
 
Figure 4. Schematic representation of ING1 functions. Modified from Guérillon et al., 2013. 
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Implicated in 
Various cancers 
For review: Ythier et al., 2008; Guérillon et al., 2014. 
Many genetics and epigenetics alterations of tumor 
suppressor genes (TSGs) or oncogenes contribute to 
cancerogenesis. Thus, the expression of tumor 
suppressor gene ING1 has been analysed in many 
tumor types. 
Adenocarcinoma of the 
esophagogastric junction 
Among 19 adenocarcinoma of the esophagogastric 
junction (AdEGJs), two tumors presented ING1b 
alterations (11%). One missense mutation at codon 
147 had a G to T transition resulting in serine to 
isoleucine substitution. The second silent mutation at 
codon 173 had a G to A transition with no amino acid 
change. In addition, p33ING1b mRNA expression 
was reduced in 63% of AdEGJs samples compared 
to normal esophageal tissues. Moreover, ING1b 
protein expression was frequently decreased or not 
detected in tumor samples, while all normal gastric 
mucosa had ING1b protein expression (Hara et al., 
2003). 
Ameloblastoma 
In the case of Ameloblastoma, a high frequency of 
loss of heterozygosity (33% - 72%) is found in the 
loci of each ING gene family member. In the case of 
ING1, 51% of 35 patients showed an allelic loss in 
the ING1 coding region. Different mechanisms, such 
as deletions, gene conversion or mitotic combination 
might be implicated to enhance INGs gene 
alterations and promote ameloblastoma 
tumorigenesis (Borkosky et al., 2010). 
Brain tumor 
In human brain tumors, ING1b mislocalization is 
observed in all of the analyzed glioma samples and 
in some glioma cell lines. However, mutations of 
ING1 seem to be infrequent. A single point mutation 
was detected in 29 brain tumor specimens (3.5%) 
manifested by an arginine to histidine substitution. 
This amino acid change is caused by a G-to-A 
transition. Furthermore, this mutation does not affect 
the expression of ING1b mRNA, but it leads to a 
cytoplasmic shift of p33ING1b, according to taking 
place in a sequence of ING1 reported to target 
p33ING1b to the nucleus (Vieyra et al., 2003). 
Breast cancer 
In breast cancer, expression of ING1 mRNA is 
decreased in 17 of 24 breast cancer tissues (71%), 
compared to normal tissues (Tokunaga et al., 2000). 
Furthermore, a downregulation of ING1 gene has 
been established in breast cancer cell lines. 
Mutations of ING1 are rare (1/377) in breast 
carcinomas (Toyama et al., 1999). In addition, 7 of 
86 invasive breast carcinoma cases showed an 
increase of p33ING1b expression in the cytoplasm, 
while the 79 cases had a low p33ING1b cytoplasmic 
expression, with 33 of them lacking absolutely 
cytoplasmic expression of p33ING1b (Nouman et 
al., 2003). 
Childhood acute lymphoblastic 
leukemia 
In childhood Acute Lymphoblastic Leukeamia 
(ALL), 78% of cases showed a decrease in the 
expression of nuclear p37ING1b which undergoes a 
shift to the cytoplasm. This translocation may 
attenuate the function of p37ING1b protein and 
plays an important role in pathogenesis of ALL 
(Nouman et al., 2002b). 
Colorectal carcinoma 
In colorectal carcinomas, no loss of alleles has been 
detected in ING1 gene. Neither Loss Of 
Heterozygosity (LOH) nor mutations have been 
observed in 29 sporadic colorectal carcinomas 
samples. It suggests that another mechanism might 
be implicated in the loss of gene. For example, 
hypermethylation of the promoter might be 
responsible for the inactivation of tumour suppressor 
genes (Sarela et al., 1999). In addition, the ratios of 
p33ING1b and p47ING1a mRNA expression were 
significantly lower in human sporadic colorectal 
tissus than those in normal tissues (Chen et al., 
2005). Moreover, 32 % of patients with Dukes'A 
colorectal cancer display a low expression of 
p33ING1b protein (Ahmed et al., 2008). 
Esophageal squamous cell cancer 
In the case of Esophageal squamous cell cancer 
(ESCC), 59 % of 31 informative cases showed allelic 
loss at chromosome 13q33-34 where ING1 is 
mapped. Four somatic missense mutations are 
located between codons 214 and 270, and two 
somatic silent mutations are located between codons 
219 and 223. All of the missense mutations found in 
ESCC were localised within the highly conserved 
PHD finger-like domain which is implicated in 
transcriptional regulation. Loss of ING1 protein 
expression has been observed in all ESCC samples, 
this absence of ING1 may contribute to ESCC 
carcinogenesis (Chen et al., 2001). 
Gastric cancer 
It has been demonstrated that 75% of tumor samples 
tested showed a significant decrease in p33ING1 
expression associated with gastric carcinogenesis. 
Moreover, a silent mutation is detected in 2/12 
gastric cancer cells with no amino acid change in 
codon 188, and only one cell line(1/12) had a 
missense mutation in codon 172 resulting in 
glutamine to lysine amino acid substitution. 
However, these findings suggest that p33ING1 acts 
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as a tumor suppressor gene even if it is preserved in 
the majority of gastric cancer (Oki et al., 1999). 
Haematological malignancies 
49 patients with heamatological malignancies and 5 
normal patients showed a predominant expression of 
p33ING1b transcript, while p24/ING1 and 
p47/ING1 transcripts are very weakly expressed. In 
addition, no p33ING1b sequence variation has been 
observed in all of the 49 patients with 
heamatological malignancies, suggesting that 
neither p33ING1b mutation, nor dysregulation of 
alternative splicing of ING1 gene are significantly 
responsible of heamatological malignancies 
progression (Bromidge et al., 2002). 
Head and neck squamous cell 
carcinoma 
In Head and Neck Squamous Cell Carcinomas 
(HNSCC), a deletion is found on chromosome 
13q33-34, where ING1 gene is mapped. A loss of 
heterozigosity has been detected in 68 % of HNSCC 
cases. Six mutations were identified in the 23 tumors 
with allelic loss, 13% showed missense mutations 
with amino acid change and the other 3 samples 
showed an alteration at codon 173 of p33ING1b 
without an amino acid change. All these mutations 
are found in the PHD finger or NLS domain of ING1 
(Gunduz et al., 2000). Another study showed that 
there is no somatic mutation in any of 20 primary 
tumors showing 13q LOH and in 5 head and neck 
cancer cell lines, suggesting an alternative factor 
implicated in this type of tumor (Sanchez-Cespedes 
et al., 2000). 
Hepatocellular carcinoma 
In hepatocellular carcinoma (HCC), p33ING1 gene 
is not frequently altered (7%). This mutation resulted 
in G to C transversion, in the codon 215, with an 
amino change (cysteine to serine) in ING1b gene. 
However, 42 % of HCC tissus had an up-regulation 
of p33ING1b, whereas 58% showed a 
downregulation of p33ING1b protein. Although the 
rate of mutation in ING1 is low, loss or inactivation 
of p33ING1b may be an important mechanism for 
malignant transformation of HCC (Zhu et al., 2005). 
Another study suggests that ING1 protein was 
expressed in either hepatocarcinoma cells or 
hepatocytes, and localized in the nuclei of 
hepatocarcinoma cells. In advanced stage group, the 
general expression level of ING1 was increased in 
the tumor tissue. Besides, transcriptional levels 
showed that ING1b is up-regulated in HCC tissus, 
whereas ING1a expression level remains unchanged 
(Chen et al., 2009). 
Lung cancer 
In lung cancer, 6/31 of primary lung cancer tumors 
and 1/30 human lung cancer cell lines showed a G to 
A transition that occurred in codon 173 located in the 
NLS domain of ING1. This substitution does not 
result in amino acid change. There is no point 
mutation detected in ING1b gene. An up-regulation 
of ING1b mRNA expression is detected in 7 of 8 
lung cancer cell lines having a p53 mutation (Okano 
et al., 2006). In the case of non-small cell lung cancer 
(NSCLC), another study demonstrated that only 2 % 
had point mutations in the coding regions of ING1b, 
but there was no missense mutation detected in 
ING1b coding region. In addition, 42 % showed a 
reduction of ING1b gene expression associated with 
p53 mutations (Kameyama et al., 2003). 
Lymphoid malignancies 
In lymphoid malignancies, many deletions and 
chromosomal translocations were observed in q33-
34 region of chromosome 13 where ING1 gene is 
mapped. A decrease in the expression of ING1 gene 
is found in 4/5 T-cell lines derived from acute 
lymphocytic leukemia. A decrease of ING1 
expression was also found in 5/11 B- cell lines 
including 2 myeloma and 2 Burkitt lymphoma cell 
lines. Moreover, no point mutation or deletion was 
detected in the 9 cell lines having reduced ING1 
expression. These findings suggest that 
transcriptional or post-transcriptional mechanisms 
are responsible of ING1 decreased expression which 
contributes to the development of lymphoid 
malignancies (Ohmori et al., 1999). 
Mantle cell lymphoma 
The genetic alteration of mantle cell lymphoma 
(MCL) is a translocation t(11;14)(q13;q32), detected 
in all MCL cases. Additional aberrations are 
implicated in lymphoma malignancies, such as the 
inactivation of tumor suppressor genes. For example, 
the expression of ING1 is decreased in all the cell 
lines. No evidence of promoter methylation of ING1 
gene has been found in MCL cell lines (Ripperger et 
al., 2007). 
Melanoma 
The p33ING1b protein expression level is 
significantly increased in 14 melanoma cell lines 
studied. An overexpression of p33ING1b mRNA 
was also found in all 6 melanoma cell lines 
examined, but it was absent in normal melanocytes. 
There is a low mutation rate (14 %) in melanoma cell 
lines. Two silent nucleotide changes have been 
detected in exon 1a in Sk-mel-110, whereas, in Sk-
mel-24, 8 nucleotide alterations in exon 2 were 
found. Seven alterations were silent and 1 missense 
alteration at codon 260 results in an aspargine to 
serine amino acid subsitution. No mutation has been 
detected in 25 samples of healthy volunteers 
suggesting that these nucleotide alterations in the 2 
melanoma cell lines are not due to a polymorphism. 
Thus, ING1 gene is not frequently mutated in 
melanoma cells. These findings demonstrated that 
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other mechanisms, such as DNA hypomethylation, 
may contribute to the overexpression of ING1 
(Campos et al., 2002). 
Another study showed a loss of nuclear p33ING1b 
expression associated with a strong or intermediate 
cytoplasmic p33ING1b expression in 35 % of the 
invasive malignant melanomas. Also, 47 % showed 
a complete loss of nuclear p33ING1b expression. 
The translocation or the shift to the cytoplasm may 
result in a loss of p33ING1b function (Nouman et al., 
2002a). 
Oral squamous cell carcinoma 
Few studies about p33ING1b role and expression in 
oral squamous cell carcinoma (OSCC) have been 
published. In normal squamous cells, p33ING1b 
showed only a nuclear expression, whereas 24 % of 
OSCC showed a shift of p33ING1b protein from the 
nucleus to the cytoplasm with a weak nuclear 
staining, and 76 % of OSCC had a negative 
expression of p33ING1b. Furthemore, p33ING1b 
shift to the cytoplasm may result in an unfonctional 
protein that enhances oncogenesis of OSCC. 
Besides, it is demonstrated that the tumors with 
p33ING1b cytoplasmic expression are more 
aggressive, however the reason is still unknown 
(Zhang et al., 2008). 
Ovarian cancer 
Among the 111 cases of ovarian carcinoma analysed, 
25 % are observed with a low or absent p33ING1b 
protein expression. Besides, a total of 32 cases 
showed a significant reduction of p33ING1b mRNA 
expression, with a decrease or absence of p33ING1b 
protein in 53 % of them. No mutation of p33ING1b 
has been detected in these samples. An allelic loss at 
the p33ING1b locus was detected in 25 % of the 
cases with a correlation between mRNA expression 
and p33ING1b protein decrease. Twenty four 
percent of 88 patients had p33ING1b promoter 
methylation. In addition, p33ING1b promoter 
methylation has been observed in two ovarian cancer 
cell lines, OVCA3 and SKOV3 (2/2). The absence 
of mutation suggests that other inactivation 
mechanisms can occur, such as histone 
deacetylation, and might contribute to p33ING1b 
silencing and tumorigenesis of ovarian cancer (Shen 
et al., 2005). 
Pancreatic carcinoma 
Only 15 % of pancreatic carcinoma specimens 
showed a reduction of p33ING1b protein expression. 
This low percentage demonstrates that there is no 
correlation between p33ING1b expression and 
clinicopathological factors. In addition, a single 
germline missense mutation located at codon 215 
has been identified in 1/40 pancreatic carcinoma 
cases. This mutation is manifested by a cysteine to 
serine substitution at codon 215 localised in the PHD 
domain of ING1. However, p33ING1b protein 
expression is still normal in this sample. 60 % of 
tumor cases showed a loss of heterozygosity (LOH) 
with no mutation detected. In addition, 2 of these 
samples have an absence of p33ING1b protein 
expression. These findings suggested that mutations 
are not the only reason for the loss of function of 
p33ING1b in pancreatic carcinomas (Yu et al., 
2004). 
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